CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 349 enrolled
Drug / intervention
PRT-201 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02110901
NCT02110901Phase 3Completed

Multicenter, Double-Blind, Placebo-Controlled Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease

Proteon Therapeutics·interventional·Posted Apr 10, 2014·Updated Jul 9, 2019

In Brief

A Phase 3 clinical trial evaluating PRT-201 and Placebo for Chronic Kidney Disease. Completed, enrolled 349 participants across 35 sites.

Detailed Summary

This research study is designed to assess the safety and effectiveness of an experimental drug called PRT-201 in patients both receiving or expecting to receive dialysis who have chronic kidney disease and who are undergoing surgery to create a new access point to their bloodstream for hemodialysis. PRT-201 is a protein that has been shown in previous research studies to help keep vessels patent when applied to the outside surface of the blood vessels (arteries and veins) in patients who undergo surgery to create an arteriovenous fistula (AVF). The purpose of this study is to determine whether PRT-201 when applied to a limited segment of your blood vessel (about 2 inches) immediately after surgery is safe and improves the patency of your AVF.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 10, 2014
Enrollment StartJul 1, 2014
Primary CompletionDec 1, 2016
Study CompletionDec 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 12.2 years ago

Interventions

PRT-201drug

Placebodrug